TransThera | 药捷安康

【2024 #ASH】 #TransThera Announces the Phase I Study Results of TT-01488, a Novel Non-Covalent BTK Inhibitor,  in Patients with Relapsed or Refractory B-cell Malignancies

2024 #ESMO Asia: #TransThera announces clinical data of #tinengotinib in combination with atezolizumab (PD-L1) in biliary tract carcinoma(BTC).

【2024 #AACR Late Breaking Research】#TransThera announces clinical data of #tinengotinib to treat patients with advanced solid tumors harboring actionable FGFR1-3 alterations NANJING, China and GAITHURSBURG, Md., April 12, 2024 TransThera Sciences, a clinical-stage biopharmaceutical company focused on inventing differentiated drugs for global patients, announced the poster presentation at the 2024 American Association for Cancer Research (AACR) to discuss the latest breaking research of tinengotinib for patients with advanced solid tumors harboring actionable FGFR1-3 alterations.   Monotherapy for patients with advanced solid tumors harboring actionable FGFR1-3 mutations: Fibroblast growth factor receptor (FGFR) alterations occur across various malignancies and are potent oncogenic drivers in multiple tumor types. FGFR inhibitors have demonstrated efficacy in several cancers with FGFR alterations. However, no effective therapies are available worldwide for patients with advanced solid tumors harboring actionable FGFR1-3 mutations currently. Tinengotinib is a unique multi-kinase inhibitor that has very distinct binding mode to FGFR 1-3 proteins, rendering it highly potent to a series of FGFR mutations, including gatekeeper mutations, molecular brake mutations, cystine binding site mutations, and others. This feature has made it highly differentiated from existing FGFR inhibitors, indicating its potential to target cancer patients bearing a broad range of FGFR mutations. The retrospective analysis of the pooled results from four clinical studies of tinengotinib in advanced solid tumors harboring actionable FGFR1-3 mutations showed efficacy in multiple tumor types, including cholangiocarcinoma, breast, prostate, urothelium, colon and head and neck cancer. Our data demonstrate 33.3% BOR and 88.2% DCR, 6.90 months mPFS. The promising results validated the novel mechanism of tinengotinib and clinical applications for potentially FGFR 1-3 altered patients with solid tumors. For more information, please visit www.transthera.com  

#TransThera Announced Global Phase 3 Clinical Trial for #Cholangiocarcinoma Authorized in the #European Union and #Orphan Drug Designation for #Tinengotinib to Treat Biliary Tract Cancer Granted by European Medicines Agency

#TransThera initiates #IND-Enabling studies for #TT-02332, a novel, highly potent and #CNS-penetrating #NLRP3 inhibitor 😁

【2024 ASCO GU】TransThera announces clinical data of tinengotinib in heavily pretreated metastatic castration-resistant prostate cancer #ASCOGU #TransThera #tinengotinib #mCRPC

【2024 ASCO GI】TransThera announces oral  and poster presentations for clinical data of tinengotinib to treat biliary tract cancers 🙌 #ASCO #TransThera #tinengotinib